<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James D Douketis, MD, FRCPC, FACP, FCCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siraj Mithoowani, MD, MHPE, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2769184212"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Non-major orthopedic surgery includes a variety of lower extremity and upper extremity surgeries that do <strong>not</strong> include major orthopedic surgeries such as total hip arthroplasty, total knee arthroplasty, hip fracture repair, and severe trauma-related orthopedic surgery (ie, pelvic fracture, severe extremity injury). While the risk of venous thromboembolism (VTE; deep venous thrombosis, pulmonary embolism) is considered high for those undergoing major lower extremity orthopedic surgery, the risk of VTE is generally much lower in those undergoing non-major orthopedic surgery, although the range of risk is wide and the population is less well studied.</p><p>Our approach to VTE prevention in adults undergoing <strong>non</strong>-major extremity orthopedic surgery is discussed in this topic and is consistent with approaches issued by the American College of Chest Physicians and the American Society of Hematology [<a href="#rid1">1,2</a>].</p><p>VTE prevention in patients undergoing major orthopedic surgery, trauma-related orthopedic surgery, and nonorthopedic surgery are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="headingAnchor" id="H2607692274"><span class="h1">TYPES OF NON-MAJOR ORTHOPEDIC EXTREMITY SURGERY</span><span class="headingEndMark"> — </span>Non-major extremity orthopedic procedures are a heterogeneous group that includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Repair of long bone above-knee fracture (eg, femur, tibial plateau) and below-knee fracture (eg, tibia, fibula, tibia-fibula) not involving the hip or knee joint and repair of soft tissue injury (which may or may not occur in association with long bone fracture) such as quadriceps and patellar tendon ruptures. (See <a class="local">'Isolated long bone above- and below-knee fracture/soft tissue injury'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arthroscopy or arthroscopic surgery of the knee and hip. (See <a class="local">'Knee arthroscopic surgery'</a> below and <a class="local">'Upper extremity procedures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone, joint, or soft tissue surgery of the ankle/foot (eg, ankle arthroscopy, carpal or tarsal bone fracture, fusion, arthrodesis, amputation, hallux valgus repair, Achilles tendon repair). (See <a class="local">'Foot and ankle surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shoulder/elbow/wrist/hand surgery (eg, fracture and non-fracture-related surgery or arthroscopy of the shoulder, rotator cuff repair; fracture surgery of the humerus, radius, or ulna; repair of elbow or wrist fracture; and carpal bone fracture or carpal tunnel release, digital repair). (See <a class="local">'Upper extremity procedures'</a> below.)</p><p></p><p>We will not be discussing surgeries involving free flap reconstruction or replantation, or trauma-related orthopedic surgery (eg, concomitant head trauma, multiple severe fractures, concomitant nerve or vascular injury), which are often high risk for VTE and are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15121.html" rel="external">"Surgical reconstruction of the lower extremity"</a> and  <a class="medical medical_review" href="/z/d/html/131498.html" rel="external">"Flap reconstruction of the lower extremity"</a> and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a> and  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p class="headingAnchor" id="H742534323"><span class="h1">GENERAL RISK ASSESSMENT</span><span class="headingEndMark"> — </span>In patients undergoing non-major orthopedic surgery of the extremity (ie, <strong>other than</strong> hip or knee arthroplasty, hip fracture repair, or severe trauma-related orthopedic surgery), we assess the risk of postoperative VTE and bleeding to evaluate the need for and safety of thromboprophylaxis.</p><p class="headingAnchor" id="H242767011"><span class="h2">Risk of thrombosis</span><span class="headingEndMark"> — </span>For patients undergoing non-major orthopedic surgery, we take a full history and examination to assess the baseline risk of the surgical procedure and other patient-specific or procedure-related risk factors for VTE. In this population, there are no validated tools to accurately estimate VTE risk. While preliminary data suggest possible value [<a href="#rid3">3</a>], we do not typically use the Caprini score  (<a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">table 1</a>) since the score has yet to be properly validated in orthopedic surgery patients [<a href="#rid4">4,5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline risk</strong> – The baseline risk of VTE in patients undergoing non-major extremity orthopedic surgery is generally considered low (eg, &lt;2 percent risk of VTE in the first three months following surgery). The generally younger age of this population and more active lifestyle compared with patients undergoing major lower extremity orthopedic surgery may contribute to the lower risk. Furthermore, early mobilization/ambulation of patients has been a significant driver of reducing post-operative VTE risk. Data describing the baseline VTE risk in this population are largely derived from observational studies, which are discussed in more detail in the sections below. (See <a class="local">'Lower extremity procedures'</a> below and <a class="local">'Upper extremity procedures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional risk factors</strong> – When assessing VTE risk, we also evaluate for additional patient-specific or procedure-related risk factors  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>) that may augment the risk above baseline:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient-specific factors that increase the risk of VTE include previous VTE, family history of VTE, and active cancer, among others  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several procedure-related factors can also increase the risk of VTE. These include the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The extent and duration of surgery (the greater the extent and duration, the higher the risk).</p><p class="bulletIndent3"><span class="glyph">-</span>Extended use of intraoperative tourniquet (although this is controversial).</p><p class="bulletIndent3"><span class="glyph">-</span>The type of anesthesia (general anesthesia has a higher risk compared with local anesthesia).</p><p class="bulletIndent3"><span class="glyph">-</span>Immobilization and casting postoperatively (immobilization and casting increase the risk).</p><p class="bulletIndent3"><span class="glyph">-</span>Select surgeries at high risk of VTE such as femur fracture, fractures around the knee, and Achilles tendon repair (eg, &gt;2 percent risk VTE in first three months following surgery). (See <a class="local">'Isolated long bone above- and below-knee fracture/soft tissue injury'</a> below and <a class="local">'Foot and ankle surgery'</a> below.)</p><p></p><p class="headingAnchor" id="H2364773014"><span class="h2">Risk of bleeding</span><span class="headingEndMark"> — </span>For patients undergoing non-major extremity orthopedic procedures in whom pharmacologic thromboprophylaxis is warranted, we obtain a full history and examination to assess the risk of major bleeding. Major bleeding is defined as fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a fall in hemoglobin of ≥2 g/dL or leading to transfusion of two or more units of whole blood or red cells, or bleeding requiring reoperation [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline risk</strong> – The American College of Chest Physicians and others have estimated that the average baseline bleeding risk in nontrauma patients is low and approximately &lt;2 percent  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 3</a>) [<a href="#rid1">1,7</a>]. However, estimates are largely derived from patients undergoing major lower extremity orthopedic surgery such as hip or knee arthroplasty or hip fracture repair. Other factors that may be affecting accurate estimates are the increasing use of thromboprophylaxis, improvements in surgical techniques, and the inclusion in trials of only patients with a low risk of bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional risk factors</strong> – We also take into consideration additional patient-specific and procedure-related risk factors. Patient-specific factors may also increase the bleeding risk. These include conditions that represent contraindications to pharmacologic thromboprophylaxis (eg, active bleeding), bleeding diatheses, thrombocytopenia (eg, platelet count &lt;50,000/microL)  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 4</a>), or conditions in which bleeding is potentially catastrophic. Epistaxis and menstrual bleeding are not contraindications to pharmacologic thromboprophylaxis.</p><p></p><p class="bulletIndent1">Most experts consider open shoulder surgery (eg, total shoulder arthroplasty) and some foot surgeries (eg, Achilles tendon surgery) to have a higher risk of bleeding (2 to 4 percent) [<a href="#rid8">8-11</a>] while other procedures like arthroscopy and hand surgeries (eg, carpal tunnel release) have a lower bleeding risk (&lt;2 percent) [<a href="#rid12">12</a>].</p><p></p><p>Use of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> as an agent to control bleeding may decrease the risk of bleeding, if used [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H881217048"><span class="h1">LOWER EXTREMITY PROCEDURES</span><span class="headingEndMark"> — </span>This includes patients with bony and soft tissue injury repair and patients undergoing knee and foot/ankle surgery. (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p>The content in this section does <strong>not</strong> apply to patients undergoing major lower extremity orthopedic procedures (eg, hip arthroplasty, knee arthroplasty, hip fracture repair), patients with severe trauma-related orthopedic or other surgery (eg, concomitant head trauma, multiple severe fractures, concomitant nerve or vascular injury), or surgeries involving free flap reconstruction or replantation. These data and protocols for thromboprophylaxis in these populations are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient", section on 'Pelvis or extremity injury'</a> and  <a class="medical medical_review" href="/z/d/html/16732.html" rel="external">"Surgical management of severe lower extremity injury", section on 'VTE prophylaxis'</a>.)</p><p class="headingAnchor" id="H3964216082"><span class="h2">Isolated long bone above- and below-knee fracture/soft tissue injury</span><span class="headingEndMark"> — </span>This includes repair of long bone above-knee fractures (eg, femur, tibial plateau), fractures around the knee, below-knee fractures (eg, tibia, fibula, tibia-fibula), and quadriceps and patella tendon repairs. (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p class="headingAnchor" id="H1102994846"><span class="h3">Recommendation</span><span class="headingEndMark"> — </span>For patients who undergo surgical repair of an isolated long bone above- or below-knee fracture/soft tissue injury that is considered at high risk of VTE, we suggest pharmacologic thromboprophylaxis rather than no prophylaxis, provided that the bleeding risk is low; this includes femoral shaft fracture, femoral neck, inter- or subtrochanteric fracture, tibial plateau fracture, patellar fracture, realignment procedures such as tibial osteotomy, and/or surgery requiring prolonged immobilization or casting. For all other patients, we suggest early and frequent ambulation rather than pharmacologic thromboprophylaxis unless patient-specific factors that place the individual at high risk for VTE are present (eg, previous VTE)  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>).</p><p>When thromboprophylaxis is chosen, we suggest low molecular weight (LMW) heparin or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. However, the optimal agent is unknown and practice varies widely. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> is frequently administered in this population, particularly in individuals with low thrombotic risk who are not yet weight-bearing, although data comparing aspirin to other approaches are indirect and dosing varies widely (eg, 81 mg/day to 325 mg/day). Prophylaxis is generally administered for the period of immobilization or casting.</p><p>This approach is based upon evidence that has consistently demonstrated that the spectrum of risk for VTE is wide in this population (&lt;1 to 6 percent) (see <a class="local">'Venous thromboembolism risk'</a> below), suggesting that select patients on the higher end of this risk range may benefit from pharmacologic thromboprophylaxis while thromboprophylaxis may not be justified for those on the lower end of this risk. For those in whom pharmacologic thromboprophylaxis is administered, data suggest that thromboprophylaxis may impact VTE rates by preventing asymptomatic or distal deep vein thrombosis (DVT) rather than symptomatic disease (ie, VTE that is clinically significant and at risk of embolization). (See <a class="local">'Efficacy of pharmacologic prophylaxis'</a> below.)</p><p class="headingAnchor" id="H2790074355"><span class="h3">Venous thromboembolism risk</span><span class="headingEndMark"> — </span>The risk of VTE with isolated long bone above-and below-knee fracture/soft tissue injury varies but is on average &lt;2 percent (range &lt;1 to 6 percent) [<a href="#rid14">14-22</a>]. On the higher end of the range are patients with femur fracture repair and those with injury that is closer in proximity to the hip or knee [<a href="#rid17">17,21</a>]. Fractures actually involving the hip (eg, femoral neck fracture, intertrochanteric fracture, subtrochanteric fracture) or knee joint (eg, distal femur, tibial plateau, patellar fracture) or realignment procedures like tibial osteotomy have a higher VTE risk that is similar to hip or knee repair/replacement procedures [<a href="#rid19">19</a>]. VTE risk in patients undergoing major orthopedic surgery is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p>Data that support this low risk in this population are typically derived from small retrospective studies [<a href="#rid14">14,17-19,22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of patients undergoing casting of the lower leg (requiring surgical or conservative management), the rate of symptomatic VTE was 1.8 percent among those who did not receive VTE prophylaxis [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter prospective cohort study included patients with a tibia, fibula, or ankle fracture (treated nonoperatively) or a patellar or foot fracture (treated operatively or conservatively). Thromboprophylaxis was not allowed during the study. The overall rate of symptomatic VTE was 7 of 1200 (0.6 percent) [<a href="#rid14">14</a>]. Two had proximal DVT; three had calf vein thrombosis; and two had pulmonary embolism (PE).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial of patients with isolated below-knee fractures, the incidence of VTE after surgically repaired, isolated tibia, fibula, or ankle fracture was 1.9 percent among those who did not receive thromboprophylaxis [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a nationwide review, the incidence of VTE during the 180-day study period following surgery for a fracture distal to the knee was 594 of 57,619 (1 percent) [<a href="#rid17">17</a>]. The patients in this study received thromboprophylaxis perioperatively, which was discontinued at discharge.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of hospitalized patients with isolated patella fracture, DVT occurred in 29 of 716 patients (4.1 percent), with one patient having bilateral limb involvement [<a href="#rid19">19</a>].</p><p></p><p>Typical patient-specific and procedure-related issues contributing to an increased risk of VTE following extremity fracture include older age, preinjury immobility, type of surgery, and immobilization and casting, which is common following fracture surgery. (See <a class="local">'Risk of thrombosis'</a> above.)</p><p class="headingAnchor" id="H2566602408"><span class="h3">Efficacy of pharmacologic prophylaxis</span><span class="headingEndMark"> — </span>Data to support anticoagulant prophylaxis in individuals undergoing surgery for isolated lower limb fracture/soft tissue injury are fraught with several methodologic limitations. These include low event rates, heterogeneity in patient outcomes (eg, symptomatic or asymptomatic DVT), a large variety of noncomparable injuries/surgeries, and patient inclusion (eg, inclusion of only low-VTE risk patients or patients with a wide VTE risk range), and early cessation of one trial [<a href="#rid18">18,20,22-29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of eight randomized trials totaling almost 3680 patients with lower leg immobilization (included patients from POT-CAST below [<a href="#rid18">18</a>] but not PRONOMOS below [<a href="#rid23">23</a>]), the incidence of symptomatic and asymptomatic VTE was lower among patients using LMW heparin compared with placebo (odds ratio [OR] 0.45) [<a href="#rid20">20</a>]. However, the range of VTE rates was wide (0 to 37 percent [LMW heparin] versus 4 to 40 percent [placebo]; OR 0.45, 95% CI 0.33-0.61; moderate-quality evidence). Results were consistent across subcategories: operated patients, conservatively treated patients, patients with fractures, patients with soft-tissue injuries, patients with proximal or symptomatic thrombosis, patients with distal thrombosis, and patients with below-knee casts (low-quality evidence). Major bleeding events were rare (0.3 percent), and the rate of PE was no different among the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label randomized trial (POT-CAST) of 1519 patients undergoing casting of the lower leg (requiring surgical or conservative management), the rate of symptomatic VTE was similar among those receiving LMW heparin for the full period of immobilization compared with those not receiving anticoagulant therapy (1.4 versus 1.8 percent) [<a href="#rid18">18</a>]. No major bleeding events occurred in either group. However, patients with a higher risk of VTE (eg, patient with previous VTE or active cancer) were excluded from this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another randomized trial (from PRONOMOS investigators) of 3604 patients who were immobilized after less extensive lower limb orthopedic surgery (eg, knee ligament repair, ankle surgery), <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (10 mg orally daily) was associated with a reduction in both symptomatic and asymptomatic VTE compared with patients treated with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> (40 mg subcutaneously once daily) (0.2 versus 1.1 percent for overall VTE rate; 0.2 versus 0.6 for symptomatic VTE) [<a href="#rid23">23</a>]. There was no difference in the rates of major bleeding between the groups (approximately 1 percent). However, interpretation of these results is limited, given that a sizeable proportion of VTE events were asymptomatic or had distal DVT (which is less likely to embolize). In addition, the study was stopped early due to poor enrollment, and the overall event rate was low.</p><p></p><p>Data to support <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in this population are also limited and indirect. Aspirin was compared with LMW heparin in a trial of over 12,000 patients (METRC) with polytrauma who underwent surgical treatment for fracture (two-thirds of patients had a lower extremity fracture excluding tarsal and meta-tarsal surgery) [<a href="#rid30">30</a>]. There was no difference in the rate of DVT (2.51 [aspirin] versus 1.71 percent [LMW heparin]), PE (1.5 percent in each group) or bleeding (14 percent each). However, most of these patients were young and had low risk for VTE. This study is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a> and  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement", section on 'Aspirin'</a>.)</p><p class="headingAnchor" id="H879595033"><span class="h2">Knee arthroscopic surgery</span><span class="headingEndMark"> — </span>This encompasses patients who undergo arthroscopic surgery of the knee. (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendation</strong> – Pharmacologic thromboprophylaxis is controversial in patients undergoing knee arthroscopic surgery, which is largely performed on an outpatient basis in otherwise young, healthy individuals. We do not routinely administer pharmacologic thromboprophylaxis in this population since the risk of symptomatic VTE appears to be low in this population. However, we advocate for an individualized approach since the individual risk may be higher in some patients compared with others. As an example, for those without additional risk factors over and above the baseline risk who are ambulatory, withholding pharmacologic thromboprophylaxis is reasonable. In contrast, for patients with additional patient-specific (eg, older age, prior DVT, contraceptive medications)  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>) or procedure-specific risk factors for VTE (eg, prolonged surgery &gt;1.5 hours), pharmacologic prophylaxis may be advisable, provided that the bleeding risk is low.</p><p></p><p class="bulletIndent1">For those in whom pharmacologic prophylaxis is chosen, we prefer LMW heparin, although <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is frequently administered, particularly in individuals with low thrombotic risk who are not yet weight-bearing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline VTE risk</strong> – Several retrospective studies of patients undergoing knee arthroscopic surgery report a low risk of VTE in this population ranging from 0.002 to 0.55 percent [<a href="#rid18">18,31-38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Best illustrating this is a Cochrane review of eight studies involving nearly 4000 patients undergoing knee arthroscopy that reported that among healthy adults, the risk of VTE was 0.002 percent and found little or no benefit from LMW heparin or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in this setting [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the POT-KAST trial, among patients undergoing knee arthroscopy who did not receive thromboprophylaxis, VTE occurred in 8 of the 1451 (0.55 percent) patients [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Patient-specific risk factors from these studies included older age, prior DVT, and contraceptive medications [<a href="#rid31">31,35,36</a>]. Procedure-related risk factors associated with VTE after knee arthroscopy include prior surgery within 30 days and operating room time &gt;1.5 hours. The type of arthroscopic surgery does not appear to alter risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of pharmacologic thromboprophylaxis</strong> – Data describing the risk benefit of pharmacologic thromboprophylaxis in patients undergoing arthroscopy and arthroscopic-assisted procedures of the knee are limited [<a href="#rid18">18,38-44</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review of eight studies involving nearly 4000 patients undergoing knee arthroscopy found little or no benefit from LMW heparin or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in this setting (risk ratio [RR] for PE 1.81, 95% CI 0.49-6.65, moderate certainty evidence; RR for symptomatic DVT 0.61, 95% CI 0.18-2.03, moderate-certainty evidence; RR for asymptomatic DVT 0.14, 95% CI 0.03-0.61, very low-certainty evidence) [<a href="#rid38">38</a>]. There was no evidence of a clear effect on major bleeding (RR 0.98, 95% CI 0.06-15.72, moderate-certainty evidence). A similar lack of benefit was reported for those taking rivaroxaban or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the POT-KAST trial, among 1543 patients undergoing arthroscopy, the rate of symptomatic VTE was similar in patients treated with LMW heparin (for eight days) compared with those not receiving prophylactic anticoagulation (0.7 versus 0.4 percent) [<a href="#rid18">18</a>]. There were no major bleeding events in either group (0.1 percent each). However, in this trial, event rates were low and high-risk patients were excluded.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another trial (ERIKA) randomly assigned 241 patients to <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or placebo for seven days after knee arthroscopy [<a href="#rid40">40</a>]. The primary composite outcome (all-cause death, symptomatic thromboembolism, asymptomatic proximal DVT at three months) occurred in significantly fewer patients in the rivaroxaban group compared with placebo (0.8 versus 6.1 percent; absolute risk difference -5.3 percent, 95% CI -11.4 to -0.8). No major bleeding was observed. The small sample size, inclusion of asymptomatic events, high exclusion rate, and low number of reconstruction procedures are limitations of this study.</p><p></p><p class="headingAnchor" id="H2599052084"><span class="h2">Hip arthroscopy</span><span class="headingEndMark"> — </span>Hip arthroscopy is a rare procedure. For patients who undergo hip arthroscopy, we follow the same principles as for arthroscopic knee surgery. (See <a class="local">'Knee arthroscopic surgery'</a> above.)</p><p>Two large database studies looked at the incidence of VTE following hip arthroscopy and found the overall incidence to be less than 1 percent (0.6 to 0.77 percent) [<a href="#rid45">45,46</a>]. Risk factors included obesity, chronic obstructive pulmonary disease, malignancy, tobacco use, and diabetes [<a href="#rid45">45,46</a>].</p><p class="headingAnchor" id="H2304654825"><span class="h2">Foot and ankle surgery</span><span class="headingEndMark"> — </span>Foot and ankle surgery includes a wide range of bone, joint, or soft tissue surgery of the ankle/foot (eg, ankle arthroscopy, tarsal bone fracture, fusion, amputation, hallux valgus repair, Achilles tendon repair). (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendation</strong> – We do <strong>not</strong> routinely administer pharmacologic thromboprophylaxis in patients undergoing foot and ankle surgery given the generally low incidence of VTE (ie, &lt;1 percent). However, we advocate an individualized approach that reserves prophylaxis for those who are considered at a high risk of VTE, provided that the bleeding risk is low. For example, we consider that pharmacologic prophylaxis is reasonable in those with procedure-specific risk factors (eg, Achilles tendon repair, prolonged immobilization is expected such as surgery for neuropathic arthropathy [ie, Charcot foot]) or patient-specific risk factors for VTE (eg, previous VTE, multiple risk factors or a family history of VTE, patients with an underlying thrombophilic disorder, active cancer). (See  <a class="medical medical_review" href="/z/d/html/15702.html" rel="external">"Surgical management of neuropathic arthropathy (Charcot foot)"</a>.)</p><p></p><p class="bulletIndent1">When pharmacologic prophylaxis is indicated, we prefer LMW heparin. We continue prophylaxis until the patient is mobile. Data suggest that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is also widely prescribed in this population [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE risk</strong> – Foot and ankle surgery procedures have an overall low risk of VTE (eg, &lt;1 percent risk of symptomatic VTE in the first three months following surgery) [<a href="#rid24">24,25,29,47-55</a>]. However, as an exception, DVT is common with Achilles tendon rupture [<a href="#rid25">25,56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a systematic review of six trials in patients undergoing isolated foot or ankle surgery, the incidence of VTE in those who did not receive thromboprophylaxis was 0.56 percent [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another systematic review, among 43,381 patients undergoing foot and ankle surgery, the incidence of symptomatic VTE was 0.4 percent [<a href="#rid24">24</a>], but the rate was higher when radiographically evident DVT was included in the analysis (ie, asymptomatic DVT; 10 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among those undergoing foot and ankle surgery, the risk of VTE is highest in patients with Achilles tendon rupture (7 percent for symptomatic DVT and 35 percent for symptomatic plus asymptomatic DVT) [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1">In these studies, patient-specific risk factors for VTE included hormone replacement, oral contraceptive use, increasing age, prior VTE, increased body mass index, inpatient status, malignancy, factor V Leiden, and nonelective surgery, non-weight bearing, and immobilization [<a href="#rid15">15,24,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of pharmacologic thromboprophylaxis</strong> – One meta-analysis of six low quality studies reported that VTE prophylaxis resulted in a lower risk for VTE (RR 0.72, 95% CI 0.55-0.94) without any change in the risk for bleeding, although the confidence limits for the latter were wide (RR 2.12, 95% CI 0.53-8.56) and the event rates for symptomatic DVT were very low [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H1430309349"><span class="h1">UPPER EXTREMITY PROCEDURES</span><span class="headingEndMark"> — </span>This encompasses patients undergoing shoulder/elbow/wrist/hand surgery such as fracture and non-fracture-related surgery or arthroscopy of the shoulder, rotator cuff repair; fracture surgery of the humerus, radius, or ulna; repair of fractures around the elbow or wrist; and carpal bone fracture or carpal tunnel release, digital nerve or tendon repair (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p>When deep vein thrombosis (DVT) occurs, it is often related to the operated upper extremity rather than affecting the lower extremity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendation</strong> – Given the generally low incidence of VTE among patients undergoing upper extremity orthopedic procedures, we do <strong>not</strong> routinely administer pharmacologic thromboprophylaxis in this population. We advocate an individualized approach that reserves prophylaxis for those who are considered at a high risk of VTE (eg, high risk procedure such as humerus fracture, anticipated prolonged immobilization; patient-specific factors such as prior VTE, thrombophilic disorder, multiple risk factors, family history of VTE), provided that the bleeding risk is low.</p><p></p><p class="bulletIndent1">In most cases when patients are considered at high risk of VTE, we prefer low molecular weight heparin, although in practice <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is frequently administered to many patients regardless of their risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE risk</strong> – Most studies in this population have reported rates of symptomatic VTE that are &lt;1 percent [<a href="#rid57">57-69</a>]. Rare retrospective case series have reported higher rates [<a href="#rid70">70-72</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a systematic review that included over 12,000 shoulder arthroplasties from nine studies, the overall incidence of VTE was 0.81 percent (0.54 percent DVT, 0.33 percent pulmonary embolism [PE]), with no significant differences in the incidences according to the type of arthroplasty [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a review of a national database, the rate of DVT and PE among over 4000 total shoulder arthroplasty surgeries was 0 and 0.20 percent, respectively [<a href="#rid67">67</a>]. Fracture surgery involving the proximal humerus was associated with slightly higher rates at 0.19 and 0.4 percent, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For elbow arthroplasty, the mean incidence of VTE (four studies) was 0.49 percent [<a href="#rid70">70</a>]. The incidence for other elbow surgeries is similarly low [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a review of over 3000 consecutive upper extremity surgeries, one case of VTE occurred following carpal tunnel release and one following digit surgery [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">In these and other studies, risk factors for VTE have included predominantly patient-specific factors such as older age, higher body mass index, prior history of DVT, family history of VTE and other medical comorbidities [<a href="#rid64">64,66-68,71,73</a>]. Procedure-related factors have included traumatic indication (particularly proximal humerus fracture), longer operative time (greater than 90 minutes), and revisional surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy pharmacologic thromboprophylaxis</strong> – Data reporting the effect of thromboprophylaxis in this population are limited to case series [<a href="#rid70">70,74-77</a>]. One small case series reported that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> did not significantly reduce VTE rates, likely because the event rate was so low [<a href="#rid75">75</a>]. Data to support aspirin in this population are indirect and limited to a subgroup of patients with polytrauma [<a href="#rid30">30</a>]. These data are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a> and  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement", section on 'Aspirin'</a>.)</p><p></p><p class="headingAnchor" id="H1192111963"><span class="h1">ROLE FOR MECHANICAL THROMBOPROPHYLAXIS</span><span class="headingEndMark"> — </span>There may be a role for mechanical thromboprophylaxis in patients undergoing non-major lower or upper extremity orthopedic procedures who are considered at high risk of VTE but who are also at high risk for bleeding or in whom anticoagulants are contraindicated.</p><p class="bulletIndent1">When used, mechanical devices (ie, sequential compression devices) are placed on one (if the involved extremity has a contraindication) or both lower extremities, even for upper extremity procedures.</p><p></p><p class="headingAnchor" id="H1775819731"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H420694710"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>The Basics topics (See  <a class="medical medical_basics" href="/z/d/html/15362.html" rel="external">"Patient education: Deep vein thrombosis (blood clot in the leg) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16922.html" rel="external">"Patient education: Pulmonary embolism (blood clot in the lung) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/696.html" rel="external">"Patient education: Pulmonary embolism (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H285397673"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Non-major orthopedic surgery includes a variety of procedures involving the lower extremity (<strong>other than</strong> hip or knee arthroplasty, hip fracture repair, or severe trauma-related orthopedic surgery) or upper extremities. (See <a class="local">'Types of non-major orthopedic extremity surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of thrombotic and bleeding risk</strong> – For patients undergoing non-major orthopedic surgery, we assess the risk of postoperative venous thromboembolism (VTE) and bleeding risk to evaluate the need for and safety of pharmacologic thromboprophylaxis. (See <a class="local">'General risk assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most patients, the baseline risk of VTE is generally low (eg, &lt;2 percent risk of VTE in the first three months following surgery). However, we assess the risk as high when procedure-related factors are present (eg, prolonged immobilization or casting, surgeries known to be at high risk for VTE such as femoral fracture repair, Achilles tendon repair) or patient-specific factors exist (eg, previous VTE)  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>). (See <a class="local">'Risk of thrombosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The baseline bleeding risk in nontrauma patients undergoing non-major orthopedic surgery is also considered low (eg, &lt;2 percent)  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 3</a>). However, we consider that shoulder and some foot surgeries have a higher risk of bleeding (2 to 4 percent) and that patient-specific factors may augment the baseline risk (eg, patients on anticoagulants). (See <a class="local">'Risk of bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repair of isolated long bone above- and below-knee fracture/soft tissue injury</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who undergo surgical repair of an isolated long bone above- or below-knee fracture/soft tissue injury that is considered at high risk of VTE, we suggest pharmacologic thromboprophylaxis rather than no prophylaxis, provided that the bleeding risk is low (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This includes femoral shaft fracture, femoral neck, inter- or subtrochanteric fracture, tibial plateau fracture, patellar fracture, realignment procedures such as tibial osteotomy, and/or surgery requiring prolonged immobilization or casting. (See <a class="local">'Isolated long bone above- and below-knee fracture/soft tissue injury'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all other patients, we suggest early and frequent ambulation with active joint range of motion rather than pharmacologic thromboprophylaxis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), unless patient-specific factors that place the individual at high risk for VTE are present (eg, active cancer, thrombophilia, multiple risk factors present, previous or family history of VTE)  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When thromboprophylaxis is chosen, we suggest low molecular weight (LMW) heparin or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, the optimal agent is unknown, and practice varies widely. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> is frequently administered in this population, particularly in individuals with low thrombotic risk who are not yet weight-bearing, but data to support it are indirect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylaxis is generally administered for the period of immobilization (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>This approach is based upon evidence that has consistently demonstrated that the risk of VTE is wide in this population (&lt;1 to 6 percent), suggesting that select patients on the higher end of this risk range may benefit from pharmacologic thromboprophylaxis, while thromboprophylaxis may not be justified for those on the lower end of this risk. For those in whom pharmacologic thromboprophylaxis is administered, data suggest that thromboprophylaxis may impact VTE rates by preventing asymptomatic or distal deep vein thrombosis rather than symptomatic disease (ie, VTE that is clinically significant and at risk of embolization). (See <a class="local">'Efficacy of pharmacologic prophylaxis'</a> above and <a class="local">'Venous thromboembolism risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Knee or hip arthroscopic surgery, foot and ankle surgery, upper extremity surgery</strong> – Patients undergoing knee or hip arthroscopic surgery, foot and ankle surgery, or upper extremity surgery do not typically require pharmacologic thromboprophylaxis, since the risk of VTE is very low in these populations. However, in patients assessed as having a higher than usual procedural risk (eg, prolonged immobilization expected, Achilles tendon repair, proximal humerus fracture) or patient-specific factors (eg, prior VTE, active cancer, thrombophilia, multiple risk factors present, family history of VTE), pharmacologic prophylaxis is reasonable. While the optimal agent is unknown, LMW heparin is appropriate, although <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is frequently administered in those considered to have low thrombotic risk. (See <a class="local">'Knee arthroscopic surgery'</a> above and <a class="local">'Foot and ankle surgery'</a> above and <a class="local">'Upper extremity procedures'</a> above.)</p><p></p><p class="headingAnchor" id="H1192488914"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Menaka Pai, MD, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S.</a></li><li><a class="nounderline abstract_t">Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019; 3:3898.</a></li><li><a class="nounderline abstract_t">Dashe J, Parisien RL, Pina M, et al. Is the Caprini Score Predictive of Venothromboembolism Events in Orthopaedic Fracture Patients? J Orthop Trauma 2019; 33:269.</a></li><li><a class="nounderline abstract_t">Bartlett MA, Mauck KF, Stephenson CR, et al. Perioperative Venous Thromboembolism Prophylaxis. Mayo Clin Proc 2020; 95:2775.</a></li><li><a class="nounderline abstract_t">Bateman DK, Dow RW, Brzezinski A, et al. Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol. J Arthroplasty 2017; 32:3735.</a></li><li><a class="nounderline abstract_t">Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692.</a></li><li><a class="nounderline abstract_t">Hill J, Treasure T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ 2010; 340:c95.</a></li><li><a class="nounderline abstract_t">Heijboer RRO, Lubberts B, Guss D, et al. Venous Thromboembolism and Bleeding Adverse Events in Lower Leg, Ankle, and Foot Orthopaedic Surgery with and without Anticoagulants. J Bone Joint Surg Am 2019; 101:539.</a></li><li><a class="nounderline abstract_t">Stone MJ, Wilks DJ, Wade RG. Hand and wrist surgery on anticoagulants and antiplatelets: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 2020; 73:1413.</a></li><li><a class="nounderline abstract_t">Lung BE, Kanjiya S, Bisogno M, et al. Preoperative indications for total shoulder arthroplasty predict adverse postoperative complications. JSES Open Access 2019; 3:99.</a></li><li><a class="nounderline abstract_t">Sager B, Ahn J, Tran J, Khazzam M. Timing and Risk Factors for Venous Thromboembolism After Rotator Cuff Repair in the 30-Day Perioperative Period. Arthroscopy 2019; 35:3011.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120:2954.</a></li><li><a class="nounderline abstract_t">Augustinus S, Mulders MAM, Gardenbroek TJ, Goslings JC. Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis. Eur J Trauma Emerg Surg 2023; 49:1247.</a></li><li><a class="nounderline abstract_t">Selby R, Geerts WH, Kreder HJ, et al. Symptomatic venous thromboembolism uncommon without thromboprophylaxis after isolated lower-limb fracture: the knee-to-ankle fracture (KAF) cohort study. J Bone Joint Surg Am 2014; 96:e83.</a></li><li><a class="nounderline abstract_t">Gouzoulis MJ, Joo PY, Kammien AJ, et al. Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture. PLoS One 2022; 17:e0276548.</a></li><li><a class="nounderline abstract_t">Nemeth B, Timp JF, van Hylckama Vlieg A, et al. High risk of recurrent venous thrombosis in patients with lower-leg cast immobilization. J Thromb Haemost 2018; 16:2218.</a></li><li><a class="nounderline abstract_t">Wahlsten LR, Eckardt H, Lyngbæk S, et al. Symptomatic venous thromboembolism following fractures distal to the knee: a nationwide Danish cohort study. J Bone Joint Surg Am 2015; 97:470.</a></li><li><a class="nounderline abstract_t">van Adrichem RA, Nemeth B, Algra A, et al. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. N Engl J Med 2017; 376:515.</a></li><li><a class="nounderline abstract_t">Tan Z, Hu H, Deng X, et al. Incidence and risk factors for deep venous thrombosis of lower extremity after surgical treatment of isolated patella fractures. J Orthop Surg Res 2021; 16:90.</a></li><li><a class="nounderline abstract_t">Zee AA, van Lieshout K, van der Heide M, et al. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Cochrane Database Syst Rev 2017; 8:CD006681.</a></li><li><a class="nounderline abstract_t">Horner D, Pandor A, Goodacre S, et al. Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review. J Thromb Haemost 2019; 17:329.</a></li><li><a class="nounderline abstract_t">Selby R, Geerts WH, Kreder HJ, et al. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. J Orthop Trauma 2015; 29:224.</a></li><li><a class="nounderline abstract_t">Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med 2020; 382:1916.</a></li><li><a class="nounderline abstract_t">Calder JD, Freeman R, Domeij-Arverud E, et al. Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery. Knee Surg Sports Traumatol Arthrosc 2016; 24:1409.</a></li><li><a class="nounderline abstract_t">Lapidus LJ, Rosfors S, Ponzer S, et al. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. J Orthop Trauma 2007; 21:52.</a></li><li><a class="nounderline abstract_t">Testroote M, Stigter W, de Visser DC, Janzing H. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev 2008; :CD006681.</a></li><li><a class="nounderline abstract_t">Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002; 347:726.</a></li><li><a class="nounderline abstract_t">Jørgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res 2002; 105:477.</a></li><li><a class="nounderline abstract_t">Bikdeli B, Visvanathan R, Jimenez D, et al. Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. Thromb Haemost 2019; 119:1686.</a></li><li><a class="nounderline abstract_t">Major Extremity Trauma Research Consortium (METRC), O'Toole RV, Stein DM, et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med 2023; 388:203.</a></li><li><a class="nounderline abstract_t">Mauck KF, Froehling DA, Daniels PR, et al. Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study. J Thromb Haemost 2013; 11:1279.</a></li><li><a class="nounderline abstract_t">Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: Systematic review and meta-analysis of benefits and harms. BMJ 2015; 350:h2747.</a></li><li><a class="nounderline abstract_t">Nemeth B, Cannegieter SC. Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: From a population-based approach to individualized therapy. Thromb Res 2019; 174:62.</a></li><li><a class="nounderline abstract_t">Abram SGF, Judge A, Beard DJ, Price AJ. Adverse outcomes after arthroscopic partial meniscectomy: a study of 700 000 procedures in the national Hospital Episode Statistics database for England. Lancet 2018; 392:2194.</a></li><li><a class="nounderline abstract_t">Maletis GB, Inacio MC, Reynolds S, Funahashi TT. Incidence of symptomatic venous thromboembolism after elective knee arthroscopy. J Bone Joint Surg Am 2012; 94:714.</a></li><li><a class="nounderline abstract_t">Martin CT, Pugely AJ, Gao Y, Wolf BR. Risk factors for thirty-day morbidity and mortality following knee arthroscopy: a review of 12,271 patients from the national surgical quality improvement program database. J Bone Joint Surg Am 2013; 95:e98 1.</a></li><li><a class="nounderline abstract_t">Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms. Br J Sports Med 2015; 49:1229.</a></li><li><a class="nounderline abstract_t">Perrotta C, Chahla J, Badariotti G, Ramos J. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev 2020; 5:CD005259.</a></li><li><a class="nounderline abstract_t">Camporese G, Bernardi E, Prandoni P, et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 2008; 149:73.</a></li><li><a class="nounderline abstract_t">Camporese G, Bernardi E, Noventa F, et al. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. Thromb Haemost 2016; 116:349.</a></li><li><a class="nounderline abstract_t">Kaye ID, Patel DN, Strauss EJ, et al. Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. Bull Hosp Jt Dis (2013) 2015; 73:243.</a></li><li><a class="nounderline abstract_t">Michot M, Conen D, Holtz D, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin. Arthroscopy 2002; 18:257.</a></li><li><a class="nounderline abstract_t">Wirth T, Schneider B, Misselwitz F, et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy 2001; 17:393.</a></li><li><a class="nounderline abstract_t">Camporese G, Bernardi E, Prandoni P, et al. Graduated compression stocking (GCS) versus low-molecular-weight heparin (LMWH) for prevention of deep vein thrombosis (DVT) after knee arthroscopy (KA): a randomized study (KANT). J Thromb Haemost 2007; 5:OT.</a></li><li><a class="nounderline abstract_t">Khazi ZM, An Q, Duchman KR, Westermann RW. Incidence and Risk Factors for Venous Thromboembolism Following Hip Arthroscopy: A Population-Based Study. Arthroscopy 2019; 35:2380.</a></li><li><a class="nounderline abstract_t">Holler JT, Halvorson RT, Salesky M, et al. Incidence of Venous Thromboembolism After Hip Arthroscopy Is Low With or Without Prophylaxis but Risk Factors Include Oral Contraceptive Use, Obesity, and Malignancy. Arthroscopy 2023; 39:981.</a></li><li><a class="nounderline abstract_t">Shah K, Thevendran G, Younger A, Pinney SJ. Deep-vein thrombosis prophylaxis in foot and ankle surgery: what is the current state of practice? Foot Ankle Spec 2015; 8:101.</a></li><li><a class="nounderline abstract_t">Carr P, Ehredt DJ Jr, Dawoodian A. Prevention of Deep Venous Thromboembolism in Foot and Ankle Surgery. Clin Podiatr Med Surg 2019; 36:21.</a></li><li><a class="nounderline abstract_t">Robinson R, Wirt TC, Barbosa C, et al. Routine Use of Low-Molecular-Weight Heparin For Deep Venous Thrombosis Prophylaxis After Foot and Ankle Surgery: A Cost-Effectiveness Analysis. J Foot Ankle Surg 2018; 57:543.</a></li><li><a class="nounderline abstract_t">Huntley SR, Abyar E, Lehtonen EJ, et al. Incidence of and Risk Factors for Venous Thromboembolism After Foot and Ankle Surgery. Foot Ankle Spec 2019; 12:218.</a></li><li><a class="nounderline abstract_t">Chao J. Deep Vein Thrombosis in Foot and Ankle Surgery. Orthop Clin North Am 2016; 47:471.</a></li><li><a class="nounderline abstract_t">Cirlincione AS, Mendicino R, Catanzariti AR, Grossman J. Low-molecular-weight heparin for deep vein thrombosis prophylaxis in foot and ankle surgery: a review. J Foot Ankle Surg 2001; 40:96.</a></li><li><a class="nounderline abstract_t">Griffiths JT, Matthews L, Pearce CJ, Calder JD. Incidence of venous thromboembolism in elective foot and ankle surgery with and without aspirin prophylaxis. J Bone Joint Surg Br 2012; 94:210.</a></li><li><a class="nounderline abstract_t">Jameson SS, Augustine A, James P, et al. Venous thromboembolic events following foot and ankle surgery in the English National Health Service. J Bone Joint Surg Br 2011; 93:490.</a></li><li><a class="nounderline abstract_t">Sultan MJ, Zhing T, Morris J, et al. Compression stockings in the management of fractures of the ankle: a randomised controlled trial. Bone Joint J 2014; 96-B:1062.</a></li><li><a class="nounderline abstract_t">Domeij-Arverud E, Labruto F, Latifi A, et al. Intermittent pneumatic compression reduces the risk of deep vein thrombosis during post-operative lower limb immobilisation: a prospective randomised trial of acute ruptures of the Achilles tendon. Bone Joint J 2015; 97-B:675.</a></li><li><a class="nounderline abstract_t">Imberti D, Ivaldo N, Murena L, et al. Venous thromboembolism in patients undergoing shoulder surgery: findings from the RECOS Registry. Thromb Res 2014; 134:273.</a></li><li><a class="nounderline abstract_t">Dattani R, Smith CD, Patel VR. The venous thromboembolic complications of shoulder and elbow surgery: a systematic review. Bone Joint J 2013; 95-B:70.</a></li><li><a class="nounderline abstract_t">Takahashi H, Yamamoto N, Nagamoto H, et al. Venous thromboembolism after elective shoulder surgery: a prospective cohort study of 175 patients. J Shoulder Elbow Surg 2014; 23:605.</a></li><li><a class="nounderline abstract_t">Wronka KS, Pritchard M, Sinha A. Incidence of symptomatic venous thrombo-embolism following shoulder surgery. Int Orthop 2014; 38:1415.</a></li><li><a class="nounderline abstract_t">Ojike NI, Bhadra AK, Giannoudis PV, Roberts CS. Venous thromboembolism in shoulder surgery: a systematic review. Acta Orthop Belg 2011; 77:281.</a></li><li><a class="nounderline abstract_t">Kuremsky MA, Cain EL Jr, Fleischli JE. Thromboembolic phenomena after arthroscopic shoulder surgery. Arthroscopy 2011; 27:1614.</a></li><li><a class="nounderline abstract_t">Heyer JH, Parker RL, Lynch T, et al. Rate of venous thromboembolism after surgical treatment of proximal humerus fractures. Arch Orthop Trauma Surg 2021; 141:403.</a></li><li><a class="nounderline abstract_t">Hastie GR, Pederson A, Redfern D. Venous thromboembolism incidence in upper limb orthopedic surgery: do these procedures increase venous thromboembolism risk? J Shoulder Elbow Surg 2014; 23:1481.</a></li><li><a class="nounderline abstract_t">Nielsen LJ, Matzen SH. Venous thromboembolism prophylaxis in plastic surgery: a survey of the practice in Denmark. J Plast Surg Hand Surg 2017; 51:122.</a></li><li><a class="nounderline abstract_t">Na SS, Kim DH, Choi BC, Cho CH. Incidence, characteristics, and risk factors of venous thromboembolism in shoulder arthroplasty-a systematic review. Int Orthop 2022; 46:2081.</a></li><li><a class="nounderline abstract_t">Jameson SS, James P, Howcroft DW, et al. Venous thromboembolic events are rare after shoulder surgery: analysis of a national database. J Shoulder Elbow Surg 2011; 20:764.</a></li><li><a class="nounderline abstract_t">Roberts DC, Warwick DJ. Updated recommendations for venous thromboembolism prophylaxis in hand, wrist and elbow surgery. J Hand Surg Eur Vol 2019; 44:1107.</a></li><li><a class="nounderline abstract_t">Badhrinarayanan S, Desai A, Watson JJ, et al. Indications, Outcomes, and Complications of Lateral Ulnar Collateral Ligament Reconstruction of the Elbow for Chronic Posterolateral Rotatory Instability: A Systematic Review. Am J Sports Med 2021; 49:830.</a></li><li><a class="nounderline abstract_t">Kadhum M, Elniel AR, Furniss D. Is venous thromboembolism prophylaxis beneficial in upper limb major joint replacement surgery? A systematic review. Shoulder Elbow 2021; 13:119.</a></li><li><a class="nounderline abstract_t">Young BL, Menendez ME, Baker DK, Ponce BA. Factors associated with in-hospital pulmonary embolism after shoulder arthroplasty. J Shoulder Elbow Surg 2015; 24:e271.</a></li><li><a class="nounderline abstract_t">Tashjian RZ, Lilly DT, Isaacson AM, et al. Incidence of and Risk Factors for Symptomatic Venous Thromboembolism After Shoulder Arthroplasty. Am J Orthop (Belle Mead NJ) 2016; 45:E379.</a></li><li><a class="nounderline abstract_t">Navarro RA, Inacio MC, Burke MF, et al. Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication. Clin Orthop Relat Res 2013; 471:1576.</a></li><li><a class="nounderline abstract_t">Aibinder WR, Sanchez-Sotelo J. Venous Thromboembolism Prophylaxis in Shoulder Surgery. Orthop Clin North Am 2018; 49:257.</a></li><li><a class="nounderline abstract_t">Alyea E, Gaston T, Austin LS, et al. The Effectiveness of Aspirin for Venous Thromboembolism Prophylaxis for Patients Undergoing Arthroscopic Rotator Cuff Repair. Orthopedics 2019; 42:e187.</a></li><li><a class="nounderline abstract_t">Anakwe RE, Middleton SD, Beresford-Cleary N, et al. Preventing venous thromboembolism in elective upper limb surgery. J Shoulder Elbow Surg 2013; 22:432.</a></li><li><a class="nounderline abstract_t">Sindhu KK, Cohen B, Blood T, et al. Upper Extremity Deep Venous Thrombosis Prophylaxis After Elective Upper Extremity Surgery. Orthopedics 2018; 41:21.</a></li></ol></div><div id="topicVersionRevision">Topic 128931 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315265" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794602" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31124908" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Is the Caprini Score Predictive of Venothromboembolism Events in Orthopaedic Fracture Patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33276846" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perioperative Venous Thromboembolism Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734614" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842354" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20106897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893235" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Venous Thromboembolism and Bleeding Adverse Events in Lower Leg, Ankle, and Foot Orthopaedic Surgery with and without Anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499185" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hand and wrist surgery on anticoagulants and antiplatelets: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334436" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preoperative indications for total shoulder arthroplasty predict adverse postoperative complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31629586" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Timing and Risk Factors for Venous Thromboembolism After Rotator Cuff Repair in the 30-Day Perioperative Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932800" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : How I treat anticoagulated patients undergoing an elective procedure or surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36512031" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875035" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Symptomatic venous thromboembolism uncommon without thromboprophylaxis after isolated lower-limb fracture: the knee-to-ankle fracture (KAF) cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36264985" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30160361" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High risk of recurrent venous thrombosis in patients with lower-leg cast immobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788303" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Symptomatic venous thromboembolism following fractures distal to the knee: a nationwide Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959702" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509241" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence and risk factors for deep venous thrombosis of lower extremity after surgical treatment of isolated patella fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780771" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30580466" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900749" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32223113" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26988553" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211270" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843725" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213943" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091045" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31430799" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652352" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23648016" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26080045" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Arthroscopic surgery for degenerative knee: Systematic review and meta-analysis of benefits and harms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579148" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: From a population-based approach to individualized therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262336" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adverse outcomes after arthroscopic partial meniscectomy: a study of 700 000 procedures in the national Hospital Episode Statistics database for England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517387" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence of symptomatic venous thromboembolism after elective knee arthroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23864189" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors for thirty-day morbidity and mortality following knee arthroscopy: a review of 12,271 patients from the national surgical quality improvement program database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26383759" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374919" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626046" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27075710" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630467" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877611" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11288011" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Graduated compression stocking (GCS) versus low-molecular-weight heparin (LMWH) for prevention of deep vein thrombosis (DVT) after knee arthroscopy (KA): a randomized study (KANT)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395174" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Incidence and Risk Factors for Venous Thromboembolism Following Hip Arthroscopy: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36334853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of Venous Thromboembolism After Hip Arthroscopy Is Low With or Without Prophylaxis but Risk Factors Include Oral Contraceptive Use, Obesity, and Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25205678" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Deep-vein thrombosis prophylaxis in foot and ankle surgery: what is the current state of practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446043" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevention of Deep Venous Thromboembolism in Foot and Ankle Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29685566" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Routine Use of Low-Molecular-Weight Heparin For Deep Venous Thrombosis Prophylaxis After Foot and Ankle Surgery: A Cost-Effectiveness Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29682981" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Incidence of and Risk Factors for Venous Thromboembolism After Foot and Ankle Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772954" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Deep Vein Thrombosis in Foot and Ankle Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11324676" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Low-molecular-weight heparin for deep vein thrombosis prophylaxis in foot and ankle surgery: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Incidence of venous thromboembolism in elective foot and ankle surgery with and without aspirin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464488" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Venous thromboembolic events following foot and ankle surgery in the English National Health Service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086122" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Compression stockings in the management of fractures of the ankle: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25922463" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intermittent pneumatic compression reduces the risk of deep vein thrombosis during post-operative lower limb immobilisation: a prospective randomised trial of acute ruptures of the Achilles tendon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916548" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Venous thromboembolism in patients undergoing shoulder surgery: findings from the RECOS Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307676" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The venous thromboembolic complications of shoulder and elbow surgery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24745310" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Venous thromboembolism after elective shoulder surgery: a prospective cohort study of 175 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24691988" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Incidence of symptomatic venous thrombo-embolism following shoulder surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21845993" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Venous thromboembolism in shoulder surgery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21925830" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Thromboembolic phenomena after arthroscopic shoulder surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32504179" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Rate of venous thromboembolism after surgical treatment of proximal humerus fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751530" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Venous thromboembolism incidence in upper limb orthopedic surgery: do these procedures increase venous thromboembolism risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310150" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Venous thromboembolism prophylaxis in plastic surgery: a survey of the practice in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35761099" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Incidence, characteristics, and risk factors of venous thromboembolism in shoulder arthroplasty-a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420324" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Venous thromboembolic events are rare after shoulder surgery: analysis of a national database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31488009" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Updated recommendations for venous thromboembolism prophylaxis in hand, wrist and elbow surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877230" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Indications, Outcomes, and Complications of Lateral Ulnar Collateral Ligament Reconstruction of the Elbow for Chronic Posterolateral Rotatory Instability: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33897843" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Is venous thromboembolism prophylaxis beneficial in upper limb major joint replacement surgery? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25976989" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Factors associated with in-hospital pulmonary embolism after shoulder arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737296" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Incidence of and Risk Factors for Symptomatic Venous Thromboembolism After Shoulder Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392993" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499826" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Venous Thromboembolism Prophylaxis in Shoulder Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30602049" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Effectiveness of Aspirin for Venous Thromboembolism Prophylaxis for Patients Undergoing Arthroscopic Rotator Cuff Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23333169" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Preventing venous thromboembolism in elective upper limb surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877326" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Upper Extremity Deep Venous Thrombosis Prophylaxis After Elective Upper Extremity Surgery.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
